For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > BUSINESS
BUSINESS
- Shionogi Nabs Japan Commercial Rights to Grunenthal’s Osteoarthritis Drug
August 5, 2022
- Izcargo Fails to Win Approval in Brazil; JCR Aims for Refiling
August 4, 2022
- Trulicity Sales Alliance Deal to Expire by 2022-End: Lilly Japan/Sumitomo
August 4, 2022
- Mitsubishi to Review Biz Plan around Medicago’s COVID Jab, Reexamine Japan Timeline Too
August 4, 2022
- Mitsubishi Tanabe’s Q1 Sales Rise 2.9% on Growth in Japan
August 4, 2022
- Lenvima/Keytruda Combo Fails in PIII HCC Trial
August 4, 2022
- Japan Pharma Market to Reach 9.4 Trillion Yen in 2030: Fuji Keizai
August 4, 2022
- AstraZeneca, Tech Nation Link Arms to Help Startups Foray into Japan, UK
August 3, 2022
- Astellas Taps Ex-AstraZeneca Exec Taniguchi as New CMO
August 3, 2022
- Sawai Grabs Japan Rights to CureApp’s NASH Therapeutic App
August 3, 2022
- Sosei, AbbVie Expand Collaboration into Neurological Arena
August 3, 2022
- Ayumi to Boost Calonal Output to 2.88 Billion Tablets, Still August Shortage Likely
August 3, 2022
- Shionogi Eyes PIII Topline Readout for COVID Pill in Aug-Sept., Sticks to H1 Approval Plan
August 2, 2022
- Nipro to Temporarily Halt Some Cefazolin Supplies, Competitors Respond with Shipment Curbs
August 2, 2022
- Ono Logs Two-Digit Growth in Q1 Earnings on Opdivo
August 2, 2022
- Astellas’ Earnings Hit by FX as Cost Rate Worsens on Overseas Inventories
August 2, 2022
- Shionogi’s Q1 Sales Up 4.2% on HIV Franchise, FX
August 2, 2022
- Moderna Takes Over Spikevax’s Japan Marketing Authorization
August 2, 2022
- Japan’s Fertility Treatment Market to Grow 44.4% by 2025: Fuji Keizai
August 1, 2022
- Daiichi Sankyo Q1 Sales Rise 6.2% on Robust Enhertu Performance, Weaker Yen
August 1, 2022
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…